



UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Technology Center 1600

Facsimile Transmission

| | | |
|-------|----------------------------------|--------------------------|
| To: | Name: | John B. Alexander, Ph.D. |
| | Company: | Edwards & Angell, LLP |
| | Fax Number: | 1 617 439 4170 |
| | Voice Phone: | 1 617 439 4444 |
| From: | Name: | Examiner David Romeo |
| | Official Fax Number: | (703) 872-9306 |
| | Official After Final Fax Number: | (703) 872-9307 |
| | Voice Phone: | 703 305-4050 |

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

Application Number: 09/716147
Attorney Docket Number: 47176-DIV2 (70342)

Mr. Alexander, Please consider the attached proposed examiner's amendment. Thank you, David Romeo.

Date and time of transmission: Monday, June 02, 2003 6:07:16 PM
Number of pages including this cover sheet: 02

Art Unit: 1647

Proposed examiner's amendment:

In the claims:

Replace claim 17 with the following claim:

17. A screening method for a compound capable of changing the binding activity of a ligand
- 5 polypeptide comprising the amino acid sequence of SEQ ID NO: 73, or its amide or ester, or a salt thereof, or a partial peptide of said ligand polypeptide, or its amide or ester, or a salt thereof, with a receptor protein comprising the amino acid sequence of SEQ ID NO: 21, or a salt thereof, or a partial peptide of said receptor protein, or a salt thereof, the method comprising making a comparison of said binding activity between:
- 10 (i) at least one case where said ligand polypeptide, or its amide or ester, or a salt thereof, or a partial peptide of said ligand polypeptide, or its amide or ester, or a salt thereof is contacted with said receptor protein or a salt thereof or a partial peptide of said receptor protein or a salt thereof, and
- (ii) at least one case where said ligand polypeptide, or its amide or ester, or a salt thereof, or a
- 15 partial peptide of said ligand polypeptide, or its amide or ester, or a salt thereof together with a sample containing the compound to be tested is contacted with said receptor protein or a salt thereof or a partial peptide of said receptor protein or a salt thereof.

Cancel claims 12-16, 18-20.